Mad cow disease blood donor ban could be dropped this summer

Chris McKeen Behind the scenes of the NZ Blood Service’s Auckland laboratory and donation facility. (File photo) A two-decade ban on blood donations due to risk of mad cow disease looks set to be lifted within six months, with an application to remove the ban now sitting with the safety regulator. The ban prevents anyone who spent six months or more in the UK, Ireland, or France between 1980 and 1996 from donating blood. When it was introduced in 2000, the ban affected about 10% of donors. Are you affected? Email [email protected] MedSafe confirmed the NZ Blood Service lodged an application this week to lift the ban, but could not confirm exactly when the assessment would be finished. It can take up to three months for MedSafe to review the application and complete the legal steps needed to lift the ban, but that can take longer depending on complexity, the regulator confirmed. Then, the Blood Service said it could take up to two months to update its systems before the change is made public. The initial goal was to have changes made this year. Blood products are medicines under the Medicines Act, which means MedSafe controls the ban, as the national drug safety regulator. Mad cow disease is officially known as Creutzfeldt-Jakob Disease (CJD). A variant of fatal disease in the UK originated from eating contaminated meat. There have been no known cases of this variant in New Zealand or Australia, according to the Blood Service. Donor Sivabalan Ramesh has an extremely rare blood type. (Video first published in June 2021) But there are no tests available to detect these conditions in blood donations. This was the reason behind the ban, which also applies to people who received blood transfusions in the UK, Ireland or France since 1980. Australia and the US both lifted the ban in 2022, which is understood to be what prompted New Zealand to consider the move. The NZ Blood Service was approached for comment.

Study: 93 million U.S. adults may benefit from semaglutide medication

Researchers from the University of California, Irvine have just published a study that projects 93 million U.S. adults that are overweight and obese may be suitable for the 2.4 mg dosage of semaglutide, a weight loss medication known under the brand name Wegovy. They projected based on the known weight loss effects (15% average weight loss) of this therapy that its use could result in 43 million fewer people with obesity, and prevent up to 1.5 million heart attacks, strokes, and other adverse cardiovascular events over 10 years. The study, US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events was published in the journal Cardiovascular Drugs and Therapy, and was led by Nathan D. Wong, PhD, professor and director of the Heart Disease Prevention Program in the Division of Cardiology at the UCI School of Medicine. Wong also recently presented his teams findings at the American College of Cardiology scientific sessions in March 2023. The analysis is based on results from the STEP 1 trial, published in 2021 in the New England Journal of Medicine, which showed the 2.4 mg dosage of semaglutide approved by the FDA for the treatment of obesity reduced body weight by an average of 14.9% along with reductions in several cardiovascular risk factors such as blood pressure and lipids. The study projected 93 million U.S. adults (based on National Health and Nutrition Examination Survey data) who are overweight or obese would fit STEP 1 eligibility criteria and that treatment with the drug would result in 43 million fewer persons with obesity. Wong and colleagues applied body mass index and other risk factor changes to cardiovascular disease risk scores among an estimated 83 million persons without pre-existing cardiovascular disease, estimating a reduction in 10-year cardiovascular disease risk of 1.8% from 10.15% to 8.34% (or a relative risk reduction of 18%), projecting up to 1.5 million cardiovascular events could be potentially prevented in 10 years. The analysis did not estimate the additional cardiovascular events that might be prevented from treatment among the approximately 10 million estimated eligible persons with cardiovascular disease. The projected 18% reduction in cardiovascular events in persons who are overweight or are obese but without cardiovascular disease compares favorably to the recently announced top line results of the SELECT trial which studied Wegovy in persons with cardiovascular disease and showed an actual 20% reduction in future cardiovascular events. “It is one of the biggest advances in the obesity and cardiovascular medicine world,” said Wong. We now have a weight control therapy that also significantly reduces cardiovascular events beyond the diabetes population where it was originally studied. It should be considered for patients who are obese or overweight with other risk factors where cardiovascular disease is their leading cause of disability and death.” Nathan D. Wong, PhD, professor and director of the Heart Disease Prevention Program in the Division of Cardiology at the UCI School of Medicine Related Stories Since drugs in this class have side effects, it is important that patients always discuss the risks and benefits of such therapies with their physician. Additionally, an appropriate dietary and physical activity regimen is always the foundation of weight management and cardiovascular risk reduction. Additionally, Wong noted that given the costs of these therapies, that better access is needed for our high risk underserved populations who may benefit from them. Wegovy is a glucagon-like peptide 1 receptor agonist (GLP1-RA) injectable therapy approved by the Federal Drug Administration (FDA) for chronic weight management in adults with who are obese or overweight with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. Wegovy is to be used in addition to a reduced calorie diet and increased physical activity. UCI School of Medicine Journal reference: Wong, N. D., et al. (2023) US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events. Cardiovascular Drugs and Therapy. doi.org/10.1007/s10557-023-07488-3.

New TAVR valve, premounted to save cardiologists time, linked to promising 30-day outcomes

The study’s technical success rate was 100%. Resheathing was required during three procedures and was successful each time with no complications. The mean procedure time was 45.1 minutes. One patient did experience cardiac tamponade as a result of perforation caused by the temporary pacemaker lead, but their condition was stabilized. Another patient experienced a disabling ischemic stroke immediately following the procedure, and they were treated with an emergency mechanical thrombectomy. “No residual neurological deficit” was observed. After 30 days, the team added, survival was 100%. Also, no myocardial infarctions, acute kidney injuries or major vascular complications were reported, and no patients were hospitalized for valve-related symptoms or congestive heart failure. A second patient did experience a minor stroke five days after the procedure. According to a neurologist who saw the patient, the “underlying cause of persistent neurological deficit at 30 days was a combination of prolonged postoperative recovery and subacute stroke.” Significant improvements were seen in the mean aortic valve gradient, peak velocity, aortic valve area and effective orifice area index after 30 days. Severe aortic regurgitation (AR) and paravalvular leak (PVL) was not seen in any patients, though moderate AR and moderate PVL were both seen in one patient with severely calcified aortic annulus anatomy. Significant improvements were also seen in quality of life questionnaires taken before the procedure and then again 30 days following the procedure. This included an improved mean six-minute walk distance. “The results of this study demonstrated the early procedural safety of the device in a patient population with intermediate or high surgical risk, as evidenced by a 0% mortality rate within 30 days,” the authors wrote. “The observed rate is comparable with that of first-generation and second-generation devices, and the low procedural mortality rates for third-generation balloon-expandable and self-expandable aortic valves implanted through the transfemoral route.” The team also emphasized that the complication rate seen during this study was comparable to what has been reported for similar devices. The two strokes were noteworthy, but Briedis and colleagues noted that strokes have always been a considerable risk associated with TAVR. “Importantly, no association was found between patients who underwent re-sheathing of the valve and incidence of any stroke,” the group added. Another key takeaway from the team’s analysis was the benefit of the premounted valve. “In comparison with other TAVR devices on the market, the average implantation time was considerably shorter,” the authors wrote. “This could be attributed to the device’s exceptional feature of being fully premounted on the delivery system in the manufacturing facilities, eliminating the need for valve assembly and crimping during the procedure, thus reducing the time required for the implantation. Finally, given the fact that this was a first-in-human experience associated with an operator’s early learning curve, the average reported procedure time might be overstated and can be reduced after getting more expertise with the Vienna TAVR system.” While much more research on this valve is still required, the authors praised its efficiency and ability to minimize the steps required to complete a TAVR procedure. The group also noted that, thanks to these advantages, it could prove to be a valuable resource for “developing countries facing logistical and economical challenges.” Read the full study here. This device has not been approved by the U.S. Food and Drug Administration.

Red Cross supports Hawaii wildfire victims, talks about local need for blood donations

ROANOKE, Va. (WDBJ) – The American Red Cross is ready to jump in to help whether there is a crisis thousands of miles away or right here at home. The headlines from Hawaii show the death toll from the Maui wildfires has pushed past 100 and the Red Cross is sending staff and volunteers to support victims. Jackie Grant is the Executive Director of the American Red Cross Southwest Virginia. She explained more about how the organization will support recovery efforts on the island as the community begins to rebuild. Meanwhile, it does not take a crisis to create a need for blood back in the communities throughout Southwest Virginia. Afton Jamerson is the Trauma Program Director at Carilion Clinic and Kait Moorman is the Trauma Education Outreach Coordinator with LewisGale Medical Center. Jamerson and Moorman joined Grant on Here @ Home to talk more about the critical need for blood and volunteer donors. The hospitals said the donations are critical to save lives and support the patients in their care. Together both healthcare systems will be hosting a blood drive with the Red Cross in the Roanoke Valley as part of a Heroes Give Here event. That blood drive will be at the Berglund Center’s Berglund Hall at 710 Williamson Road, Roanoke. The drive is scheduled for Thursday, Aug. 24 from 9 a.m. to 3 p.m. People interested in donating can call 1-800-733-2767 or go to RedCrossBlood.org and type in Heroes to schedule an appointment. Copyright 2023 WDBJ. All rights reserved.

Franklin on Strategies to Ameliorate the Effect of Social Determinants on CRC Screening Rates

Isabelle Franklin, medical student, Kaiser Permanente Bernard J. Tyson School of Medicine, discusses strategies healthcare providers can implement to address or ameliorate disparities in place that are affecting screening rates in colorectal cancer (CRC). Findings from a cross-sectional study on the effect of social determinants of health on CRC screening rates at Kaiser Permanente were presented at the 2023 ASCO Annual Meeting. Of the 3,443 patients who completed the Kaiser Permanente National Social Needs Survey in 2020, a significant correlation between unmet self-reported social needs and lower rates of screening was identified. These self-reported social needs included severe financial strain, feelings of social isolation, and food insecurity. Moreover, patients who were advanced in age, who were not insured, and those whose primary language was not English had lower CRC screening rates, indicating the correlation between demographic factors and CRC screening completion. These findings indicate the importance of investing in social and hospital-led programs to mitigate barriers to screening completion in CRC. To do so, it is first necessary to obtain information on a patient’s potential disparities early on, Franklin states. This can be done through intake screening survey when patients arrive at the clinic, or by requiring providers to ask their patients about any challenges accessing care during the visit, Franklin suggests. Once a patient’s needs have been identified, providers should implement measures, identify local organizations, and share appropriate resources to help patients meet their basic needs, Franklin continues. At Kaiser Permanente, the pilot program, Thrive Local, has been developed to help providers ensure their patients’ have knowledge of and access to community resources and organizations, Franklin details. Thrive Local involves the use of a database containing this information that can be filtered by type of social need and by a patient’s zip code, she explains. Furthermore, its integration with patients’ electronic health records allows providers to directly refer their patients to these organizations using the patient portal. This allows providers to receive real-time confirmation that their patients have connected with the recommended resources, Franklin concludes.

Randall Discusses the Importance of Identifying and Managing Chondroblastoma in Clinical Practice

R. Lor Randall, MD, FACS Despite being considered a rare, noncancerous bone tumor, chondrosarcoma often necessitates aggressive treatment due to its potential for metastasizing. Accordingly, it is vital to confidently differentiate patients with chondrosarcoma from those with bone malignancies in clinic, particularly when it comes to atypical disease presentations, says R. Lor Randall, MD, FACS. “We’re talking about an uncommon tumor with [some] uncommon presentations. It’s something that doesn’t get a lot of attention in the oncology world but might be [a condition] that people should know about,” said Randall, the David Linn Endowed Chair for Orthopedic Surgery, the chair of the Department of Orthopedic Surgery, and a professor at UC Davis Comprehensive Cancer Center in Sacramento, California. In an interview with OncLive®, Randall explained the difference between noncancerous chondroblastoma and other bone neoplasms, detailed the typical diagnosis and treatment of this rare condition, and emphasized the importance of pediatric and medical oncologists being able to identify it in clinic. OncLive: What is chondroblastoma, and how does it differ from other hematologic malignancies? Randall: Chondroblastoma is not a malignancy. It’s a benign tumor of the bone usually in young people, but it can mimic an aggressive bone neoplasm in appearance. Chondroblastoma is a somewhat aggressive benign neoplasm of bone, meaning it must be treated aggressively with surgery sometimes; however, radiographically and imaging-wise, it could be confused for something like a bone malignancy. It is possible that medical oncologists or other types of oncologists beyond orthopedic oncologists might see someone with a potential chondroblastoma. It’s important to realize that these are very rare [neoplasms], and they make up less than 1% of all bone tumors. They tend to [present] in young people and tend to [occur] in the epiphysis or apophysis of a skeletally immature person. How is chondroblastoma typically diagnosed? The workup usually [involves] referral to an orthopedic oncologist, who in their expertise will probably be able to determine whether this is a chondroblastoma and then treated surgically. A very small number of patients can go on to develop recurrences in the same area, and there have been some sparse case reports of it spreading in a benign way to the lungs. We’ve recently published a couple of papers [on unusual chondroblastoma cases]. One was [published] by me [and detailed an incidence of] chondroblastoma that was recurrent in the pelvis of an older person. [This was] unusual in that it’s [in an] older [person] and [located] in the pelvis. My partner [published a case study of] one in the finger, and it’s not very common in the finger. Why is chondroblastoma more frequently observed in younger patients? We don’t know the medical answer to that, per se, but we think it probably has to do with the fact that these patients are skeletally immature, and their growth plate is very active. There might be some sort of inclusion cyst of the growth plate in the epiphysis leading to this sort of satellite area in the bone. What is the typical management approach for this condition? Does the treatment of chondroblastoma differ when dealing withunusual presentations? Generally speaking, they’re treated with surgical removal, and there’s different ways by which that is done. They tend to arise in anatomically-challenging areas, [particularly] between a joint and a growth plate where there’s not a lot of room for error. You don’t want to create any damage to the growth plate or to the joint, and you have to be very strategic and precise in how you go after these. It does lend itself to management with techniques such as surgical navigation, computerized navigation, and other techniques that have come online in the past 5 to 10 years. [These] enable the surgeon to be much more precise in their surgical ablation of [chondroblastomas]. Given the rarity of this condition, can chondroblastoma mimic any other conditions? Because chondroblastomas evolve in a very distinct part of the bone in a young person, the differential diagnosis is relatively limited. If it arises in an adult or it’s very advanced, things like osteosarcoma, Ewing sarcoma, and other types of bone sarcomas would be in the differential diagnosis. At this time, is there any ongoing or planned research focused on chondroblastoma? There may be some research on applied surgical techniques. Although we don’t understand the entire pathophysiology [of chondroblastoma], it’s rare and treatable enough that there’s not a lot of laboratory research going into it. Because of its anatomic location, many surgical oncologists, particularly orthopedic oncologists, are using some of the latest applications in technology to treat these in that scenario of investigation. What is your main takeaway message for academic and community oncologists who might not see this condition very often? Particularly for the pediatric oncologists, if they are seeing someone with a destructive lesion in the bone that is in the epiphysis, which is the area right underneath the joint space, they should [consider] chondroblastoma. Obviously, they’ll confer with the radiologists and orthopedic oncologists, but it is something to consider.If [they are] referred a patient with a destructive lesion in this area, they should be able to counsel patients that there are benign things that can look like this, as chondroblastoma is benign. [They can tell these patients] not to be too alarmed, but that we must establish the diagnosis. In the grand scheme of things, there are very rare case reports of chondrosarcoma expanding into the lungs and things of that sort. If a medical oncologist or pediatric oncologist is seeing someone with a chondroblastoma, performing at least a chest radiograph is not inappropriate if there are concerns about aggressiveness.

Rare, potentially fatal bacterial infection found in recently dead person on Long Island

New York health officials issued guidance after a rare but potentially deadly bacterial infection was discovered in a recently deceased person on Long Island. Gov. Kathy Hochul said Wednesday that vibrosis, which can cause skin breakdown and ulcers, was found in an individual in Suffolk County who had recently died. The state added that fatal cases have also been identified in Connecticut recently. “While rare, the vibrio bacteria has unfortunately made it to this region and can be extraordinarily dangerous,” Hochul said. “As we investigate further, it is critical that all New Yorkers stay vigilant and take responsible precautions to keep themselves and their loved ones safe.” The governor and State Health Commissioner Dr. James McDonald said that the best ways to avoid potential vibriosis infections is to protect open wounds from seawater, particularly warm seawater, as well as for those with compromised immune systems to avoid raw or undercooked shellfish, which could carry the bacteria. While we continue to investigate the source of this rare infection, it is important for residents to remain aware and vigilant on precautions that can be taken. As always, if any residents have health concerns we encourage them to contact their health care provider,” said Suffolk County Executive Steve Bellone. What is vibriosis? According to the Centers for Disease Control and Prevention, the vibrio bacteria naturally live in coastal waters, and are more common during warm weather months between May and October. The most common way people contract the bacteria is by eating raw or undercooked shellfish, particularly oysters. Some species of vibrio can cause a rash or skin infection when exposed to salt water or brackish water (mixture of fresh and salt water). The CDC said that those with chronic liver disease are most at risk to contract the bacteria infection. About 80,000 cases are found each year in the U.S., the CDC says, with more than half a result of consuming contaminated food. Vibrosis is responsible for about 100 deaths each year, according to the CDC. Symptoms and treatment While most who contract vibrosis will recover in about three or so days with no long-term effects, a small percentage of those who get it require intensive care or even amputation, the CDC states. The New York Department of Health said that the bacteria can cause skin breakdown and ulcers, and said that health care providers should consider vibrosis when diagnosing wound infections or sepsis of unknown origins. For those who get vibrosis from consuming contaminated food, symptoms can include diarrhea, stomach cramps, vomiting, fever and chills, according to the state health department. Exposure can also lead to ear infections.

Rare Flesh-Eating Bacteria Kills At Least 8; What You Need To Know

ACROSS AMERICA — Health officials are warning of a rare flesh-eating bacterium known as Vibrio vulnificus, found naturally in warm coastal waters, that has killed multiple people along the East Coast this summer. Two people died in Connecticut and another on Long Island after becoming infected, health officials in both states said this week. In the warmer coastal waters off Florida, where surface water temperatures have soared past 100 degrees Fahrenheit this summer, 25 people have been infected with Vibrio vulnificus and five people have died, according to the Florida Vibrio infections are commonly associated with eating raw or undercooked oysters and other seafood, but also occur when people with open wounds or cuts come in contact with seawater or brackish water where the bacteria are present, according to the U.S. Centers for Disease Control and Prevention. Three people in all were hospitalized in Connecticut after becoming infected, according to state health officials Two of the three Vibrio vulnificus infections reported in that state were wound infections not associated with seafood. The third infection was a Connecticut resident who consumed raw oysters at an out-of-state establishment. The bacteria is “extraordinarily dangerous,” New York Gov. Kathy Hochul said after a Long Island resident died as a result of the infection. People infected by the Vibrio vulnificus bacteria often require intensive care or limb amputations, and about 1 in 5 die, often within a day or two of becoming ill, according to the CDC. People at greatest risk for illness from the infection are those with weakened immune systems and the elderly. Some Vibrio vulnificus infections lead to necrotizing fasciitis, a severe infection in which the flesh around an open wound dies, inspiring the “flesh-eating bacteria” moniker. The necrotizing fasciitis can be caused by more than one type of bacteria, according to the CDC. Signs and symptoms of Vibrio vulnificus infection can include: Watery diarrhea, often accompanied by stomach cramping, nausea, vomiting, and fever. For bloodstream infection: fever, chills, dangerously low blood pressure, and blistering skin lesions. For wound infection, which may spread to the rest of the body: fever, redness, pain, swelling, warmth, discoloration, and discharge (leaking fluids). The CDC suggests following these precautions: Don’t eat raw or undercooked oysters or other shellfish. If you have a wound (including from a recent surgery, piercing, or tattoo), stay out of saltwater or brackish water, if possible. This includes wading at the beach. Cover your wound with a waterproof bandage if it could come into contact with salt water, brackish water, marine life, or raw or undercooked seafood and its juices. This contact can happen during everyday activities, such as swimming, fishing, or walking on the beach. Wash wounds and cuts thoroughly with soap and water after they have contact with salt water, brackish water, marine life, raw seafood, or its juices. Besides occurring naturally in warm coastal waters, Vibrio vulnificus infections have also been associated with hurricanes, storm surges and coastal flooding.

Reduce Blood Pressure By Doing This Simple Exercise

Key Takeaways Exercises like wall squats and planks are good for reducing blood pressure—even more so than cardio, according to a recent report. Researchers say while isometric movements—exercises where you engage muscles without moving—benefit heart health, these exercises should be complementary to your regular workout routine, not replace it entirely. Growing research on the benefits of isometric exercise might influence the current health recommendations (which tout cardio) for improving blood pressure. There’s good news for people who don’t like lifting weights or running outside: Recent research found that you don’t need to move to improve your blood pressure. A meta analysis published in the British Journal of Sports Medicine found that static isometric exercises—exercises where you engage muscles without moving—might be more effective than other workouts when it comes to lowering blood pressure. Researchers analyzed 270 clinical trials that documented the effects of exercise lasting two or more weeks on resting blood pressure. The team, based out of Canterbury Christ Church University in Canterbury, U.K., found that isometric exercises were the most effective in improving both systolic and diastolic blood pressure over cardio, strength training, and high intensity interval training (HIIT). Researchers looked at three kinds of isometric exercises in particular, including squeezing a handgrip, holding a leg extension machine in place, and wall squats. The wall squats (or wall sits) were found to be the most effective isometric exercise of them all. “We believe this may be due to the larger muscle mass used performing the wall squat compared to other methods of performing isometric exercise training,” Jamie O’Driscoll, PhD, a reader in cardiovascular physiology at Canterbury Christ Church University and co-author of the report, told Verywell Health. It’s important to note, however, that the researchers concluded aerobic exercise, HIIT, and dynamic resistance training (such as body-weight squats and lifting weights) are still all effective at lowering blood pressure, too. The team says that isometric exercise should be used to complement other forms of movement, not replace it. Robert Ross, PhD, a professor at the School of Kinesiology and Health Studies at Queen’s University in Kingston, Ontario, said the research is very encouraging for people who want to lower or control blood pressure through exercise. “If someone’s sought to decrease blood pressure—if that was the reason for undertaking exercise—then the good news is isometric exercise, resistance exercise, and classic aerobic exercise are all associated with reductions in systolic and diastolic blood pressure,” Ross told Verywell. The Benefits of Isometric Exercise Ross said that the exact mechanisms that underlie the benefits of isometric exercise on blood pressure are not completely understood yet. But exercise, in general, is known to help the heart be able to pump more blood with less effort and slow heart rate. Much research has shown that exercise has positive effects on hypertension (high blood pressure) and reduces both systolic and diastolic blood pressure. What’s more, exercise can help people lose weight, and hypertension can be associated with overweight and obesity. And, unlike needing an hour to schedule in a spin class or having your running shoes handy, isometric exercise is convenient: It’s time efficient and requires no workout equipment. O’Driscoll said that this allows people to perform exercises like planks or wall squats easily at home or at work during a break. It also doesn’t take hours of sweating in a gym to get the benefits. Ross said research shows that three to four sets of two-minute isometric exercises with one- to two-minutes of rest in between is associated with reducing blood pressure. “If someone doesn’t have 150 minutes one week to perform moderate- to vigorous-physical activity, then I suppose they could say, ‘Well, if I have 10 to 15 minutes to perform this isometric type of exercise…there’s benefit with respect to blood pressure,’” Ross said. Changing Current Recommendations The authors of the new report suggest that it might be time to review the current exercise guidelines for the treatment of high blood pressure. Right now, much guidance suggests aerobic movement, such as running or brisk walking, as the most beneficial form of exercise for managing blood pressure. The researchers wrote that these recommendations are largely based on data that might be out of date as it does not include newer forms of exercise, such as HIIT and isometric exercise—exercises we now know are very beneficial to blood pressure. The American Heart Association currently says that most people should get at least 150 minutes of moderate-intensity physical activity, such as brisk walking or cycling, a week to manage blood pressure. O’Driscoll said his team is currently developing an international collaborative project with other health organizations to discuss recommendations. “Isometric exercise training is an emerging and promising exercise mode for reducing resting blood pressure and may have a role which is complementary to traditional modes of exercise—not as a substitute,” he said. “Given the youth of this line of evidence, large-scale randomized controlled trials and several subdomains of this literature still require further exploration.” Any Movement Is Better Than None While isometric workouts are seen to be most effective on improving blood pressure, both O’Driscoll and Ross said that any form of exercise is better than none, and will have a positive impact on overall health. This means if you love to power walk but haven’t mastered a plank, don’t fret: You’re still helping your heart. “The findings from the study are very important since they demonstrate that all exercise modes investigated provide significant reductions in resting blood pressure, which is very encouraging,” O’Driscoll said. “The wider literature also supports the positive value of performing even a little exercise or physical activity for health. From a public health perspective, even a little is great; something is definitely better than nothing.” What This Means For You Isometric exercises like planks and wall squats might improve your blood pressure more than cardio, according to a new meta analysis. This means that adding these types of exercises to your workout can benefit both systolic and diastolic blood pressure. Verywell

Antibiotic a game-changer for horses with Clostridioides difficile infections – study

Image by Miguel Muñoz Hierro A timely and prompt diagnosis in horses of a Clostridioides difficile infection leading to treatment with the antibiotic metronidazole improves outcomes, researchers report. The spore-forming bacterium is one of the causes of colitis (colon inflammation) in humans, especially during antimicrobial treatment and hospitalisation. C. difficile has also been isolated from animals, which are often symptom-free. However, the bacterium is known to cause disease in certain animals, including horses and pigs. In horses, it is one of the most important causes of colitis. Cases in horses have been reported worldwide, Eri Uchida-Fujii, Hidekazu Niwa and their fellow researchers noted in the journal Scientific Reports. Disease in horses ranges from mild to severe, and can be fatal. Around 6 to 8% of healthy horses are also thought to harbour C. difficile. Researchers set out to perform a molecular study of C. difficile samples taken from C. difficile cases among Japanese Thoroughbreds. They also sought to evaluate the disease-causing ability of each genotype by linking their genetic analysis to case outcomes. Their work centered on 34 cases from 2010 to 2021, from which 38 C. difficile strains were isolated. All of the horses developed severe colitis. Twenty-two of the horses (64.7%) were hospitalised at the onset of colitis. Outcomes were balanced for hospitalisation rates at the onset of colitis. The study team found that the death rates of cases treated with metronidazole (65.0%) were significantly lower than untreated cases, in which all died. Overall, nearly 80% of the horses died or were euthanised. The study team noted that in 2013 veterinarians started to use metronidazole for C. difficile cases at the two equine hospitals at the center of the study. An earlier study that reviewed the same cases suggested that metronidazole treatment reduced the mortality rate, even though the number of cases was too low to obtain adequate statistical power. The effect of metronidazole treatment was clearly significant, they said. Treatment with metronidazole would be a major factor for recovery from C. difficile in these cases, the study team said, even though the accumulation of experience by the veterinarians, early diagnosis, and improvements in supportive care might also have contributed to better outcomes. “Our study suggests that metronidazole treatment is needed for horses with adequately diagnosed C. difficile infections,” they concluded. In addition, monitoring the number of cases and their prognosis in horses should be continued to establish better approaches for the treatment and prevention of such infections. Finally, to understand the transmission route of C. difficile and to prevent healthcare-associated infections in horses, strain-based surveillance of the bacterium should be continued, they said. Genotyping for C. difficile of animal origin is important for understanding the presence and transmission of the pathogen among humans, animals, and the environment. “Further investigations of C. difficile infections in horses might contribute to understanding its potential role as a zoonotic pathogen in terms of One Health.” The study team comprised Uchida-Fujii, Niwa, Yuta Kinoshita and Takanori Ueno, all with the Microbiology Division, part of the Equine Research Institute of the Japan Racing Association; Mitsutoshi Senoh and Haru Kato, with Japan’s National Institute of Infectious Diseases; and Hiroshi Mita, with the Clinical Veterinary Medicine Division, part of the Equine Research Institute at the Japan Racing Association. Uchida-Fujii, E., Niwa, H., Senoh, M. et al. Clostridioides difficile infection in thoroughbred horses in Japan from 2010 to 2021. Sci Rep 13, 13099 (2023). https://doi.org/10.1038/s41598-023-40157-x The study, published under a Creative Commons License, can be read here. • Receive a notification when a new article is posted: